Author

Margherita Costanza Maregatti

ONE THIRD OF CELIAC PATIENTS DOES NOT PRESENT ANY SIGNS OF DISEASE ACTIVITY IN CASE OF OCCASIONAL GLUTEN INGESTION: RESULTS FROM AN ENDOSCOPIC-ENTEROSCOPIC STUDY
ONE THIRD OF CELIAC PATIENTS DOES NOT PRESENT ANY SIGNS OF DISEASE ACTIVITY IN CASE OF OCCASIONAL GLUTEN INGESTION: RESULTS FROM AN ENDOSCOPIC-ENTEROSCOPIC STUDY

Margherita Costanza Maregatti  et al.

ONE THIRD OF CELIAC PATIENTS DOES NOT PRESENT ANY SIGNS OF DISEASE ACTIVITY IN CASE OF OCCASIONAL GLUTEN INGESTION: RESULTS FROM AN ENDOSCOPIC-ENTEROSCOPIC STUDY
ONE THIRD OF CELIAC PATIENTS DOES NOT PRESENT ANY SIGNS OF DISEASE ACTIVITY IN CASE OF OCCASIONAL GLUTEN INGESTION: RESULTS FROM AN ENDOSCOPIC-ENTEROSCOPIC STUDY

MAINTENANCE OF CLINICAL BIOCHEMICAL AND TRANSMURAL REMISSION IN IBD PATIENTS SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB
MAINTENANCE OF CLINICAL BIOCHEMICAL AND TRANSMURAL REMISSION IN IBD PATIENTS SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB

Margherita Costanza Maregatti  et al.

SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB FORMULATION DETERMINES A REDUCTION OF ANTIDRUG ANTIBODY LEVELS
SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB FORMULATION DETERMINES A REDUCTION OF ANTIDRUG ANTIBODY LEVELS

Margherita Costanza Maregatti  et al.

TELEMONITORING IBD WITH THE APP CARE4TODAY IBD: A REAL-LIFE CASE-CONTROL STUDY
TELEMONITORING IBD WITH THE APP CARE4TODAY IBD: A REAL-LIFE CASE-CONTROL STUDY

Margherita Costanza Maregatti  et al.

PROMOTION OF PHYSICAL ACTIVITY WITH A MOBILE APP IS SUPERIOR TO PRESCRIPTION ALONE IN IMPROVING SYMPTOMS IN PATIENTS WITH IRRITABLE BOWEL SYNDROME: A RANDOMIZED CONTROLLED TRIAL
PROMOTION OF PHYSICAL ACTIVITY WITH A MOBILE APP IS SUPERIOR TO PRESCRIPTION ALONE IN IMPROVING SYMPTOMS IN PATIENTS WITH IRRITABLE BOWEL SYNDROME: A RANDOMIZED CONTROLLED TRIAL

Margherita Costanza Maregatti  et al.

Item 1 - 6 / 6
1